Cargando…
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity
Oncolytic viruses (OVs) encoding various transgenes are being evaluated for cancer immunotherapy. Diverse factors such as cytokines, immune checkpoint inhibitors, tumor-associated antigens, and T cell engagers have been exploited as transgenes. These modifications are primarily aimed to reverse the...
Autores principales: | Xie, Jun, Wang, Shaowei, Zhong, Yunhong, Gao, Ming, Tian, Xuezhang, Zhang, Liting, Pan, Dongli, Qin, Qingsong, Wu, Bing, Lan, Ke, Sun, Zhi-Jun, Zhang, Junjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200819/ https://www.ncbi.nlm.nih.gov/pubmed/37223114 http://dx.doi.org/10.1016/j.omto.2023.04.006 |
Ejemplares similares
-
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018) -
Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016) -
Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo
por: Yin, Lei, et al.
Publicado: (2017) -
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021) -
Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)